🔴 ICCM extends pullback as selling stockholders plan to offer 5.5 million shares, following 200%+ rally

ICCM is trading at $6.66 (5.1% down) in pre-market, extending a sharp pullback.

• The decline follows an announcement on June 25, 2026, that certain stockholders plan to sell 5.5 million ordinary shares, adding to downward pressure after a 200%+ multi-day surge.
• This comes after a 24.5% slide on June 25, 2026, driven by investors locking in gains from the rally fueled by strong ProSense adoption.
• The downward trend continues despite IceCure Medical recently regaining compliance with Nasdaq’s minimum bid price requirement.